CTOs on the Move

Synaptogenix

www.synaptogen.com

 
Synaptogenix is a clinical-stage biotech company leveraging Bryostatin-1 and its analogues to discover and develop targeted therapeutics for neurodegenerative diseases and developmental disorders.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.synaptogen.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 973.242.0005

Executives

Name Title Contact Details

Funding

Synaptogenix raised $14M on 01/21/2021
Synaptogenix raised $12.5M on 06/14/2021

Similar Companies

Forticell Bioscience

Forticell Bioscience is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Gossamer Bio

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio`s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need,

Aurion Biotech

With offices in Seattle, Boston and Tokyo, Aurion Biotech is a clinical-stage biotech company, whose mission is to restore vision to millions of patients with its life-changing regenerative therapies. The Company`s first candidate is for the treatment of corneal edema secondary to endothelial dysfunction, and is one of the first clinically validated cell therapies for corneal care. Aurion Biotech is the recipient of the prestigious Prix Galien award for best start-up in biotech. The Company is preparing for clinical trials in the U.S. Privately held, Aurion Biotech is backed by leading investors that include Deerfield, Alcon, Petrichor, Flying L Partners, Falcon Vision / KKR, and Visionary Ventures.

Sapience Therapeutics

Sapience Therapeutics is a preclinical-stage biotechnology company focused on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Our drug development program involves translating science into novel therapies, and our initial goal is to develop a first-in-class treatment for glioblastoma multiforme (GBM), which is the most severe and deadly form of brain cancer.

Q-State Biosciences

Q-State Biosciences is a technology-derived medicines company based in Cambridge, MA, that combines advanced human cellular models, unique measurement engineering and AI / machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.